Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2017

View Archived Issues

SFX-01 protects against gait anomalies in the spontaneous STR/Ort model of osteoarthritis

VAX-DC/MM immunotherapy shows disease stabilizing activity in heavily pretreated multiple myeloma

D-512 demonstrates superior antiparkinsonian efficacy to ropinirole in rat model

Pharmacological inhibition of NOX4 as a promising new approach in cancer therapy

Ritter Pharmaceuticals discloses phase III plans regarding RP-G28

Champions Oncology to develop patient-derived xenograft models with ALCMI

Nortis receives NIH phase II SBIR fast track grant

Celgene's CC-671, a dual TTK/CLK2 inhibitor for the treatment of triple negative breast cancer

Exclusive license to fully human PD-1 antibody GLS-010 is granted to Arcus Biosciences

Toray Industries divulges novel nuclear receptor ROR-gamma antagonists

Novel excitatory amino acid transporter 3 inhibitors discovered at Roche

Shanghai Fochon Pharmaceutical, Fochon Pharma patent CDK4 and CDK6 inhibitors

Patient recruitment underway in phase II trial of SK-1405 in subjects with uremic pruritus

MacroGenics starts enrollment in first-in-human trial of MGD-013

Novartis and MMV launch phase IIb trial of antimalarial KAF-156 in adults and children

Medix initiates phase III trial of tesofensine in obesity

Ethris, AstraZeneca and MedImmune enter collaboration for respiratory mRNA therapies

Participant enrollment underway in phase II trial of concizumab in hemophilia A and B patients

Actelion initiates phase I trial of macitentan/tadalafil fixed-dose-combination

Cormedix receives NIH research grant to develop advanced antimicrobial hydrogels

JDRF enters collaboration with IBM to identify risk factors for type 1 diabetes in children

Bristol-Myers Squibb enrolls participants in phase Ib/II trial of BMS-813160

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...